¼¼°èÀÇ ±â°üÁö°æ ½ÃÀå
Bronchoscopes
»óǰÄÚµå : 1766923
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 456 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,222,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,666,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

±â°üÁö°æ ¼¼°è ½ÃÀåÀº 2030³â±îÁö 50¾ï ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 35¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ±â°üÁö°æ ¼¼°è ½ÃÀåÀº 2024³âºÎÅÍ 2030³â±îÁö CAGR 5.9%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 50¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ ³»½Ã°æÀº CAGR 6.4%¸¦ ±â·ÏÇÏ¸ç ºÐ¼® ±â°£ Á¾·á±îÁö 30¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ½Ã°¢È­ ¹× ¹®¼­È­ ½Ã½ºÅÛ ºÐ¾ßÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ µ¿¾È CAGR 5.5%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº ÃßÁ¤ 9¾ï 2,420¸¸ ´Þ·¯, Áß±¹Àº CAGR 8.8%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ±â°üÁö°æ ½ÃÀåÀº 2024³â¿¡´Â 9¾ï 2,420¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦ ´ë±¹ÀÎ Áß±¹Àº ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGR 8.8%¸¦ ±â·ÏÇϸç 2030³â±îÁö 11¾ï ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖ°í, ºÐ¼® ±â°£ µ¿¾È CAGRÀº °¢°¢ 3.1%¿Í 5.3%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 3.6%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°è ±â°üÁö°æ ½ÃÀå - ÁÖ¿ä µ¿Çâ ¹× ÃËÁø¿äÀÎ ¿ä¾à

±â¼ú ¹ßÀüÀº ±â°üÁö°æ ½ÃÀåÀ» ¾î¶»°Ô Çü¼ºÇϰí Àִ°¡?

±â°üÁö°æÀº ±â¼úÀÇ ¹ßÀü°ú ÇÔ²² ºü¸£°Ô ÁøÈ­Çϰí ÀÖÀ¸¸ç, º¸´Ù È¿°úÀûÀ̰í ÃÖ¼Òħ½ÀÀûÀÎ ½Ã¼ú·Î ȯÀÚÀÇ ¿¹Èĸ¦ °³¼±Çϰí ÀÖ½À´Ï´Ù. ±â°üÁö°æÀº ȯÀÚÀÇ ±âµµ¿Í Æó ³»ºÎ¸¦ °üÂûÇÏ´Â µ¥ »ç¿ëµÇ´Â ÀÇ·á±â±â·Î, ÀϹÝÀûÀ¸·Î Æó ÁúȯÀÇ Áø´Ü, Æó»ö Á¦°Å, »ý°ËÀ» À§ÇØ »ç¿ëµË´Ï´Ù. ±âÁ¸ÀÇ ±â°üÁö°æÀº °æ¼º ¸ðµ¨¿¡¼­ ¿¬¼º ¸ðµ¨·Î ÁøÈ­ÇÏ¿© ´õ Á¤È®Çϰí, ºÒÆíÇÔÀÌ ÀûÀ¸¸ç, ½Ã¼ú Áß À§ÇèÀ» ÁÙÀÏ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ±×·¯³ª ÃÖ±Ù ±â¼ú ¹ßÀüÀ¸·Î ºñµð¿À ±â°üÁö°æ°ú ±¤¼¶À¯ ±â°üÁö°æ ½Ã½ºÅÛÀÌ µµÀÔµÇ¾î ´õ ³ªÀº ½Ã°¢È­, ´õ ³ªÀº Á¶ÀÛ¼º, ´õ ³ôÀº ÇØ»óµµÀÇ À̹Ì¡ÀÌ °¡´ÉÇØÁ³½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼ú Çõ½ÅÀ» ÅëÇØ ÀÇ»ç´Â Æó¾Ï, Æó·Å, ¸¸¼ºÆó¼â¼ºÆóÁúȯ(COPD) µîÀ» ½±°Ô Áø´ÜÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù.

±³Â÷ ¿À¿° ¹× º´¿ø³» °¨¿°(HAI)¿¡ ´ëÇÑ ¿ì·Á·Î ÀÎÇØ ÀÏȸ¿ë ±â°üÁö°æÀÌ Àα⸦ ²ø°í ÀÖ½À´Ï´Ù. Àç»ç¿ë °¡´ÉÇÑ ±â°üÁö°æÀº Àå±âÀûÀ¸·Î ºñ¿ë È¿À²ÀûÀÌÁö¸¸, ¾ö°ÝÇÑ ¼¼Ã´ ¹× ¸ê±Õ ÇÁ·ÎÅäÄÝÀÌ ÇÊ¿äÇÏ°í ¶§·Î´Â ½ÇÆÐÇÒ ¼ö ÀÖ¾î °¨¿° À§ÇèÀÌ ³ô¾ÆÁý´Ï´Ù. ÀÏȸ¿ë ±â°üÁö°æÀº ÀÌ·¯ÇÑ À§ÇèÀ» ¾ø¾Ö°í, À̹ÌÁö ǰÁú ÀúÇÏ ¾øÀÌ ¹«±ÕÀûÀÌ°í ¾ÈÀüÇÑ ´ë¾ÈÀ» Á¦°øÇÕ´Ï´Ù. ÀΰøÁö´É(AI)°ú ¸Ó½Å·¯´×ÀÇ ÅëÇÕµµ °³¹ß ºÐ¾ß Áß Çϳª·Î, ½Ç½Ã°£ µ¥ÀÌÅÍ ºÐ¼®À» Áö¿øÇÏ¿© Àǻ簡 ¼öÀÛ¾÷ °Ë»ç¿¡¼­ ³õÄ¥ ¼ö ÀÖ´Â Á¶±â ¾ÏÀ̳ª º´º¯°ú °°Àº ÀÌ»ó ¡Èĸ¦ ¹ß°ßÇÒ ¼ö ÀÖµµ·Ï µ½½À´Ï´Ù. ÀÌ·¯ÇÑ ¹ßÀüÀ¸·Î º¸´Ù Á¤±³Çϰí ȯÀÚ Ä£È­ÀûÀÎ ±â°üÁö°æ µµÀÔÀÌ ÁøÇàµÇ°í ÀÖ½À´Ï´Ù.

È£Èí±âÁúȯÀÇ Áø´Ü°ú Ä¡·á¿¡¼­ ±â°üÁö°æÀÌ ÇÏ´Â ¿ªÇÒÀº ¹«¾ùÀΰ¡?

±â°üÁö°æÀº Æó¾Ï, õ½Ä, COPD, ±â°üÁö¿° µî È£Èí±âÁúȯÀÇ Áø´Ü°ú Ä¡·á¿¡ ÇʼöÀûÀÎ µµ±¸ÀÔ´Ï´Ù. ±â°üÁö°æÀ» ÅëÇØ ÀÇ»ç´Â ±âµµ¸¦ À°¾ÈÀ¸·Î °Ë»çÇϰí Ãß°¡ °Ë»ç¸¦ À§ÇØ Á¶Á÷À̳ª ¾×ü »ùÇÃ(»ý°Ë)À» äÃëÇÒ ¼ö ÀÖ½À´Ï´Ù. Æó¾ÏÀÇ °æ¿ì ±â°üÁö°æÀº Á¶±â Áø´Ü¿¡ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí Ä¡·á ¼ºÀûÀ» Å©°Ô Çâ»ó½Ãų ¼ö ÀÖ½À´Ï´Ù. ±â°üÁö°æÀ» ÅëÇØ ÀÇ»ç´Â Àǽɽº·¯¿î ºÎÀ§¿¡¼­ Á¤È®ÇÑ »ý°ËÀ» ÇÒ ¼ö ÀÖÀ¸¸ç, Ä¡·á ÇÁ·ÎÅäÄÝÀ» ¼±ÅÃÇÏ´Â µ¥ µµ¿òÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ ±â°üÁö°æÀº ±âµµ¸¦ ¸·´Â À̹°Áú°ú Á¡¾× ¸·ÈûÀ» Á¦°ÅÇÏ¿© ¸¸¼º È£Èí±âÁúȯ ȯÀÚÀÇ È£ÈíÀ» °³¼±Çϰí ÇÕº´ÁõÀÇ À§ÇèÀ» ÁÙÀÏ ¼ö ÀÖ½À´Ï´Ù.

ÁßȯÀÚ Ä¡·á¿¡¼­ ±â°üÁö°æÀº ÀΰøÈ£Èí ÁßÀΠȯÀÚÀÇ ±âµµ Æó¼â, ÃâÇ÷, °¨¿° Æò°¡¿¡ »ç¿ëµË´Ï´Ù. ¶ÇÇÑ ±â°üÁö°æÀº ½ºÅÙÆ®¸¦ »ðÀÔÇÏ¿© ±âµµÀÇ °³ÅëÀ» À¯ÁöÇϰųª ±â°üÁöÆóÆ÷¼¼Ã´(BAL, Æó¸¦ ½Ä¿°¼ö·Î ¼¼Ã´ÇÏ°í ½ÇÇè½Ç ºÐ¼®¿ë ¾×ü¸¦ äÃëÇÏ´Â °Í)°ú °°Àº Ç¥Àû Ä¡·áÀÇ °¡À̵忡µµ »ç¿ëµË´Ï´Ù. Èí¿¬, °øÇØ, °í·ÉÈ­ µîÀÇ ¿äÀÎÀ¸·Î ÀÎÇÑ È£Èí±âÁúȯÀÇ Áõ°¡·Î ±â°üÁö°æ ¼ö¿ä´Â Àü ¼¼°èÀûÀ¸·Î Áõ°¡Çϰí ÀÖ½À´Ï´Ù. Æó °ü·Ã ÁúȯÀÇ À¯º´·üÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ½Å¼ÓÇϰí Á¤È®Çϸç ÃÖ¼Òħ½ÀÀûÀÎ Áø´Ü ¹× Ä¡·á ¿É¼ÇÀ» Á¦°øÇϴ ÷´Ü ±â°üÁö°æ µµ±¸¿¡ ´ëÇÑ ¼ö¿äµµ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

ÀÏȸ¿ë ±â°üÁö°æÀº °¨¿° °ü¸® ¹®Á¦¸¦ ¾î¶»°Ô ÇØ°áÇϰí Àִ°¡?

ÀÏȸ¿ë ±â°üÁö°æÀº °¨¿° °ü¸® ¹®Á¦, ƯÈ÷ ±³Â÷ ¿À¿° ¹× º´¿ø³» °¨¿°(HAI) À§Çè¿¡ ´ëÇÑ ÇØ°áÃ¥À¸·Î Á¡Á¡ ´õ ³Î¸® º¸±ÞµÇ°í ÀÖ½À´Ï´Ù. Àç»ç¿ë °¡´ÉÇÑ ±â°üÁö°æÀº ¸Å¹ø »ç¿ëÇÒ ¶§¸¶´Ù ´ë´ëÀûÀÎ ¼¼Ã´°ú ¸ê±ÕÀÌ ÇÊ¿äÇϸç, ¸ê±Õ °úÁ¤ÀÌ Ã¶ÀúÇÏÁö ¾ÊÀ¸¸é À§ÇèÇÒ ¼ö ÀÖ½À´Ï´Ù. ¾ö°ÝÇÑ ÇÁ·ÎÅäÄÝ¿¡µµ ºÒ±¸Çϰí Àçó¸® ÁֱⰡ Á¶±Ý¸¸ À߸øµÇ¾îµµ ¹ÚÅ׸®¾Æ, ¹ÙÀÌ·¯½º ¹× ±âŸ º´¿ø±ÕÀÌ È¯ÀÚ¿¡¼­ ´Ù¸¥ ȯÀÚ¿¡°Ô °¨¿°µÉ ¼ö ÀÖ½À´Ï´Ù. ÀÏȸ¿ë ±â°üÁö°æÀº °¢ ȯÀÚ°¡ ½Ã¼úÀ» À§ÇØ »õ·Ó°í ¸ê±ÕµÈ ±â±¸¸¦ ¹Þµµ·ÏÇÔÀ¸·Î½á ÀÌ·¯ÇÑ À§ÇèÀ» Á¦°ÅÇÕ´Ï´Ù.

ÀÏȸ¿ë ±â°üÁö ³»½Ã°æÀº °¨¿° À§ÇèÀ» ÁÙÀÌ´Â °Í ¿Ü¿¡µµ ¼¼Ã´ ¹× Àç󸮸¦ À§ÇÑ Àåºñ, Àη ¹× ½Ã°£ÀÌ ÇÊ¿äÇÏÁö ¾Ê±â ¶§¹®¿¡ ¹°·ù Ãø¸é¿¡¼­µµ ÀÌÁ¡ÀÌ ÀÖ½À´Ï´Ù. Àå±âÀûÀ¸·Î´Â °¨¿°, ¼ö¸®, À¯Áöº¸¼ö·Î ÀÎÇÑ ´Ù¿îŸÀÓ°ú °ü·ÃµÈ ºñ¿ëÀ» Àý°¨ÇÏ¿© ºñ¿ë È¿À²ÀûÀÎ ¼Ö·ç¼ÇÀ» Á¦°øÇÕ´Ï´Ù. Ç×±ÕÁ¦ ³»¼º ¹ÚÅ׸®¾ÆÀÇ Áõ°¡¿Í ȯÀÚ ¾ÈÀü¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö¸é¼­ ÀÏȸ¿ë ±â°üÁö°æÀ¸·ÎÀÇ ÀüȯÀÌ ´õ¿í °¡¼ÓÈ­µÇ°í ÀÖ½À´Ï´Ù. ÀÇ·á ¼­ºñ½º Á¦°øÀÚ°¡ °¨¿° ¿¹¹æÀ» ¿ì¼±½ÃÇÏ´Â °¡¿îµ¥, ÀÏȸ¿ë ±â°üÁö°æ ¼ö¿ä´Â ƯÈ÷ ÁßȯÀÚ½Ç, ÀÀ±Þ½Ç, ¿Ü·¡ µî¿¡¼­ È®´ëµÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

±â°üÁö°æ ½ÃÀåÀÇ ¼ºÀåÀ» ÃËÁøÇÏ´Â ¿äÀÎÀº ¹«¾ùÀΰ¡?

±â°üÁö°æ ½ÃÀåÀÇ ¼ºÀåÀº È£Èí±âÁúȯÀÇ À¯º´·ü Áõ°¡, ±â°üÁö°æ ±â¼úÀÇ ¹ßÀü, ÃÖ¼Òħ½ÀÀû Áø´Ü µµ±¸¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡ µî ¿©·¯ ¿äÀο¡ ÀÇÇØ ÀÌ·ç¾îÁý´Ï´Ù. °í·ÉÈ­, °øÇØ, Èí¿¬ µîÀ¸·Î ÀÎÇØ Æó¾Ï, õ½Ä, COPD µîÀÇ Áúº´ÀÌ È®»êµÊ¿¡ µû¶ó È¿°úÀûÀÎ Áø´Ü ¹× Ä¡·á µµ±¸ÀÇ Çʿ伺ÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ±â°üÁö°æÀº ±âµµÀÇ Á÷Á¢ °¡½ÃÈ­, »ý°Ë, Ç¥Àû Ä¡·á¸¦ °¡´ÉÇÏ°Ô ÇÏ¿© ÀÌ·¯ÇÑ ÁúȯÀÇ °ü¸®¿¡ ÇʼöÀûÀÔ´Ï´Ù.

ºñµð¿À ±â°üÁö°æ, AI Áö¿ø ±â°üÁö°æ µî ÷´Ü ±â°üÁö°æ ±â¼úÀÇ °³¹ß·Î È£Èí±â Áø´Ü ¹× Ä¡·áÀÇ Á¤È®¼º°ú À¯È¿¼ºÀÌ Çâ»óµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, °¨¿° ¹æÁö ¹× ±³Â÷ ¿À¿°¿¡ ´ëÇÑ ¿ì·Á·Î ÀÎÇØ ÀÏȸ¿ë ±â°üÁö°æÀ¸·ÎÀÇ ÀüȯÀÌ ½ÃÀå ¼ºÀåÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ±â°üÁö°æÀº ±âÁ¸ÀÇ ¿Ü°úÀû ¼ö¼úÀ» ´ëüÇÒ ¼ö ÀÖ´Â ÃÖ¼Òħ½ÀÀû Ä¡·á¹ýÀ̱⠶§¹®¿¡ ¿Ü·¡ ȯÀÚ ¹× ÃÖ¼Òħ½ÀÀû ¼ö¼ú¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡µµ ½ÃÀå ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ÀÇ·áÁø°ú ȯÀÚ°¡ º¸´Ù È¿À²ÀûÀÌ°í ¾ÈÀüÇϸç ȯÀÚ Ä£È­ÀûÀÎ Áø´Ü µµ±¸¸¦ ¿ä±¸ÇÔ¿¡ µû¶ó ¼¼°è ±â°üÁö°æ ½ÃÀåÀº Áö¼ÓÀûÀÎ ¼ºÀå¼¼¸¦ º¸ÀÏ °ÍÀ¸·Î Àü¸ÁµË´Ï´Ù.

ºÎ¹®

Á¦Ç°(³»½Ã°æ, ½Ã°¢È­ ¹× ¹®¼­È­ ½Ã½ºÅÛ, ±âŸ Á¦Ç°), ¿ëµµ(Àç»ç¿ë °¡´É ±â±â, ÀÏȸ¿ë ±â±â), ÃÖÁ¾ ¿ëµµ(±â°üÁö Ä¡·á, ±â°üÁö Áø´Ü), ÃÖÁ¾»ç¿ë(º´¿ø, ASCs ¹× Ŭ¸®´Ð)

Á¶»ç ´ë»ó ±â¾÷ »ç·Ê

AI ÅëÇÕ

¿ì¸®´Â °ËÁõµÈ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI ÅøÀ» ÅëÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ Çõ½ÅÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â LLM ¹× ¾÷°è °íÀ¯ÀÇ SLMÀ» Á¶È¸ÇÏ´Â ÀϹÝÀûÀÎ ±Ô¹ü¿¡ µû¸£´Â ´ë½Å ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾çÀÇ ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»çÀÇ ±¹°¡, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±â¹ÝÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¸ÅÃâ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº °¨¼Ò, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû ¹× °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Bronchoscopes Market to Reach US$5.0 Billion by 2030

The global market for Bronchoscopes estimated at US$3.5 Billion in the year 2024, is expected to reach US$5.0 Billion by 2030, growing at a CAGR of 5.9% over the analysis period 2024-2030. Endoscopes, one of the segments analyzed in the report, is expected to record a 6.4% CAGR and reach US$3.0 Billion by the end of the analysis period. Growth in the Visualization & Documentation Systems segment is estimated at 5.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$924.2 Million While China is Forecast to Grow at 8.8% CAGR

The Bronchoscopes market in the U.S. is estimated at US$924.2 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.1 Billion by the year 2030 trailing a CAGR of 8.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.1% and 5.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.6% CAGR.

Global Bronchoscopes Market - Key Trends & Drivers Summarized

How Are Technological Advancements Shaping the Bronchoscope Market?

Bronchoscopes are evolving rapidly with advancements in technology, making procedures more effective, minimally invasive, and improving patient outcomes. A bronchoscope is a medical instrument used to view the inside of a patient's airways and lungs, typically to diagnose lung diseases, remove obstructions, or perform biopsies. Traditional bronchoscopes have evolved from rigid to flexible models, allowing for greater precision, less discomfort, and reduced risk during procedures. However, the most recent technological advancements have introduced video bronchoscopes and fiber-optic bronchoscopy systems, which offer enhanced visualization, better maneuverability, and higher resolution imaging. These innovations have made it easier for physicians to diagnose conditions such as lung cancer, pneumonia, and chronic obstructive pulmonary disease (COPD).

Single-use bronchoscopes are gaining popularity due to concerns over cross-contamination and hospital-acquired infections (HAIs). Reusable bronchoscopes, while cost-effective in the long run, require rigorous cleaning and sterilization protocols that can sometimes fail, increasing the risk of infection. Single-use bronchoscopes eliminate this risk, offering a sterile and safe alternative without compromising imaging quality. Another area of development is the integration of artificial intelligence (AI) and machine learning, which aids in real-time data analysis, assisting physicians in detecting abnormalities such as early-stage cancer or lesions that might be missed through manual examination. These advancements are driving the adoption of more sophisticated and patient-friendly bronchoscopes.

What Role Do Bronchoscopes Play in Diagnosing and Treating Respiratory Conditions?

Bronchoscopes are indispensable tools in the diagnosis and treatment of respiratory diseases, including lung cancer, asthma, COPD, and bronchitis. They allow physicians to visually inspect the airways and collect tissue or fluid samples (biopsies) for further testing. In the case of lung cancer, bronchoscopes play a critical role in early diagnosis, which significantly improves treatment outcomes. They enable physicians to take precise biopsies from suspicious areas, guiding the choice of treatment protocols. Additionally, bronchoscopes can help remove foreign objects or mucus plugs that may block airways, improving breathing and reducing the risk of complications in patients with chronic respiratory conditions.

In critical care settings, bronchoscopes are used to evaluate airway obstructions, bleeding, or infections in ventilated patients. They are also used to guide procedures such as placing stents to keep airways open or delivering targeted treatments like bronchoalveolar lavage (BAL), where the lungs are flushed with saline to collect fluid for laboratory analysis. The growing incidence of respiratory diseases, driven by factors such as smoking, pollution, and aging populations, is increasing the demand for bronchoscopes worldwide. As the prevalence of lung-related diseases rises, the need for advanced bronchoscopy tools that provide quick, accurate, and minimally invasive diagnostic and therapeutic options is also expanding.

How Are Single-Use Bronchoscopes Addressing Infection Control Concerns?

Single-use bronchoscopes are becoming increasingly popular as a solution to infection control concerns, particularly the risk of cross-contamination and hospital-acquired infections (HAIs). Reusable bronchoscopes, which require extensive cleaning and sterilization between uses, pose a risk if the sterilization process is not thoroughly executed. Despite stringent protocols, even small lapses in the reprocessing cycle can lead to the transmission of bacteria, viruses, or other pathogens from one patient to another. Single-use bronchoscopes eliminate this risk by ensuring that each patient receives a brand-new, sterile device for their procedure.

In addition to reducing infection risks, single-use bronchoscopes offer logistical benefits by eliminating the need for cleaning and reprocessing equipment, staff, and time. They provide a cost-effective solution in the long run by reducing costs associated with infections, repairs, and downtime due to maintenance. The rise in antimicrobial resistance and heightened awareness of patient safety are further driving the shift toward disposable bronchoscopes. As healthcare providers prioritize infection prevention, the demand for single-use bronchoscopes is expected to grow, particularly in intensive care units (ICUs), emergency departments, and outpatient settings.

What Factors Are Driving the Growth of the Bronchoscope Market?

The growth of the bronchoscope market is driven by several factors, including the increasing prevalence of respiratory diseases, advancements in bronchoscopy technology, and the rising demand for minimally invasive diagnostic tools. As conditions such as lung cancer, asthma, and COPD become more prevalent due to aging populations, pollution, and smoking, the need for effective diagnostic and therapeutic tools is increasing. Bronchoscopes, which allow for direct visualization of the airways, biopsies, and targeted treatments, are critical in managing these diseases.

The development of more advanced bronchoscope technologies, such as video bronchoscopes and AI-assisted bronchoscopy, is enhancing the precision and effectiveness of respiratory diagnostics and treatments. Additionally, the shift toward single-use bronchoscopes, driven by concerns over infection control and cross-contamination, is propelling market growth. The increasing demand for outpatient and minimally invasive procedures is also contributing to the market's expansion, as bronchoscopes offer a less invasive alternative to more traditional surgical methods. As healthcare providers and patients seek more efficient, safer, and patient-friendly diagnostic tools, the global bronchoscope market is poised for sustained growth.

SCOPE OF STUDY:

The report analyzes the Bronchoscopes market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product (Endoscopes, Visualization & Documentation Systems, Other Products); Usability (Reusable Equipment, Disposable Equipment); Application (Bronchial Treatment, Bronchial Diagnosis); End-Use (Hospitals, ASCs & Clinics)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 36 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â